Brolucizumab 6mg + Brolucizumab 6mg
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Macular Polypoidal Choroidal Vasculopathy (PCV)
Conditions
Macular Polypoidal Choroidal Vasculopathy (PCV)
Trial Timeline
Feb 6, 2023 โ Sep 10, 2025
NCT ID
NCT05666804About Brolucizumab 6mg + Brolucizumab 6mg
Brolucizumab 6mg + Brolucizumab 6mg is a phase 3 stage product being developed by Novartis for Macular Polypoidal Choroidal Vasculopathy (PCV). The current trial status is completed. This product is registered under clinical trial identifier NCT05666804. Target conditions include Macular Polypoidal Choroidal Vasculopathy (PCV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05666804 | Phase 3 | Completed |
Competing Products
20 competing products in Macular Polypoidal Choroidal Vasculopathy (PCV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA + Sham + IVT aflibercept | Clearside Biomedical | Phase 2 | 44 |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin | Clearside Biomedical | Phase 3 | 69 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovistaยฎ + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |